Literature DB >> 21419756

Autotaxin as a novel serum marker of liver fibrosis.

Hayato Nakagawa1, Hitoshi Ikeda, Kazuhiro Nakamura, Ryunosuke Ohkawa, Ryota Masuzaki, Ryosuke Tateishi, Haruhiko Yoshida, Naoko Watanabe, Kazuaki Tejima, Yukio Kume, Tomomi Iwai, Atsushi Suzuki, Tomoaki Tomiya, Yukiko Inoue, Takako Nishikawa, Natsuko Ohtomo, Yasushi Tanoue, Masao Omata, Koji Igarashi, Junken Aoki, Kazuhiko Koike, Yutaka Yatomi.   

Abstract

BACKGROUND: The clinical significance of autotaxin (ATX), a key enzyme for the production of the bioactive lysophospholipid lysophosphatidic acid remains unknown. Serum ATX enzymatic activity reportedly increases in parallel with liver fibrosis and exhibits a gender difference.
METHODS: Serum ATX antigen level, measured easier than the activity, was evaluated as a marker of liver fibrosis in 2 cohorts of chronic liver disease caused by hepatitis C virus.
RESULTS: In the first cohort, serum ATX level correlated significantly with liver fibrosis stage and was the best parameter for prediction of cirrhosis with an area under the receiver operating characteristic curve (AUROC) of 0.756 in male and 0.760 in female, when compared with serum hyaluronic acid and aminotransferase-to-platelet ratio index, an established marker of liver fibrosis. In another cohort, serum ATX level correlated significantly with liver stiffness, a novel reliable marker of liver fibrosis, being the second-best parameter in male (AUROC, 0.799) and in female (AUROC, 0.876) for prediction of significant fibrosis, and the best parameter in male (AUROC, 0.863) and the third-best parameter in female (AUROC, 0.872) for prediction of cirrhosis, both of which were judged by liver stiffness.
CONCLUSIONS: Serum ATX level may be a novel marker of liver fibrosis.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21419756     DOI: 10.1016/j.cca.2011.03.014

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  27 in total

1.  Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma.

Authors:  Shih-Chi Su; Xiaoxiao Hu; Patrick A Kenney; Megan M Merrill; Kara N Babaian; Xiu-Ying Zhang; Tapati Maity; Shun-Fa Yang; Xin Lin; Christopher G Wood
Journal:  Clin Cancer Res       Date:  2013-10-11       Impact factor: 12.531

Review 2.  Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression.

Authors:  Lorenzo Federico; Kang Jin Jeong; Christopher P Vellano; Gordon B Mills
Journal:  J Lipid Res       Date:  2015-05-14       Impact factor: 5.922

Review 3.  Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis.

Authors:  Mari Gotoh; Yuko Fujiwara; Junming Yue; Jianxiong Liu; SueChin Lee; James Fells; Ayako Uchiyama; Kimiko Murakami-Murofushi; Stephen Kennel; Jonathan Wall; Renukadevi Patil; Renuka Gupte; Louisa Balazs; Duane D Miller; Gabor J Tigyi
Journal:  Biochem Soc Trans       Date:  2012-02       Impact factor: 5.407

4.  During Hepatitis C Virus (HCV) Infection and HCV-HIV Coinfection, an Elevated Plasma Level of Autotaxin Is Associated With Lysophosphatidic Acid and Markers of Immune Activation That Normalize During Interferon-Free HCV Therapy.

Authors:  Lenche Kostadinova; Carey L Shive; Chelsey Judge; Elizabeth Zebrowski; Anita Compan; Kelsey Rife; Amy Hirsch; Yngve Falck-Ytter; Daniela M Schlatzer; Xiaolin Li; Mark R Chance; Benigno Rodriguez; Daniel L Popkin; Donald D Anthony
Journal:  J Infect Dis       Date:  2016-08-17       Impact factor: 5.226

5.  Characterization of the properties of a selective, orally bioavailable autotaxin inhibitor in preclinical models of advanced stages of liver fibrosis.

Authors:  Manuel Baader; Tom Bretschneider; Andre Broermann; Joerg F Rippmann; Birgit Stierstorfer; Christian A Kuttruff; Michael Mark
Journal:  Br J Pharmacol       Date:  2018-01-17       Impact factor: 8.739

6.  Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis.

Authors:  Katharine E Black; Evgeny Berdyshev; Gretchen Bain; Flavia V Castelino; Barry S Shea; Clemens K Probst; Benjamin A Fontaine; Irina Bronova; Lance Goulet; David Lagares; Neil Ahluwalia; Rachel S Knipe; Viswanathan Natarajan; Andrew M Tager
Journal:  FASEB J       Date:  2016-03-22       Impact factor: 5.191

7.  Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition.

Authors:  Shigeki Nakagawa; Lan Wei; Won Min Song; Takaaki Higashi; Sarani Ghoshal; Rosa S Kim; C Billie Bian; Suguru Yamada; Xiaochen Sun; Anu Venkatesh; Nicolas Goossens; Gretchen Bain; Gregory Y Lauwers; Anna P Koh; Mohamed El-Abtah; Noor B Ahmad; Hiroki Hoshida; Derek J Erstad; Ganesh Gunasekaran; Youngmin Lee; Ming-Lung Yu; Wan-Long Chuang; Chia-Yen Dai; Masahiro Kobayashi; Hiromitsu Kumada; Toru Beppu; Hideo Baba; Milind Mahajan; Venugopalan D Nair; Michael Lanuti; Augusto Villanueva; Angelo Sangiovanni; Massimo Iavarone; Massimo Colombo; Josep M Llovet; Aravind Subramanian; Andrew M Tager; Scott L Friedman; Thomas F Baumert; Myron E Schwarz; Raymond T Chung; Kenneth K Tanabe; Bin Zhang; Bryan C Fuchs; Yujin Hoshida
Journal:  Cancer Cell       Date:  2016-12-12       Impact factor: 38.585

8.  Serum autotaxin is a parameter for the severity of liver cirrhosis and overall survival in patients with liver cirrhosis--a prospective cohort study.

Authors:  Thomas Pleli; Daniel Martin; Bernd Kronenberger; Friederike Brunner; Verena Köberle; Georgios Grammatikos; Harald Farnik; Yolanda Martinez; Fabian Finkelmeier; Sandra Labocha; Nerea Ferreirós; Stefan Zeuzem; Albrecht Piiper; Oliver Waidmann
Journal:  PLoS One       Date:  2014-07-25       Impact factor: 3.240

9.  Higher LPA2 and LPA6 mRNA Levels in Hepatocellular Carcinoma Are Associated with Poorer Differentiation, Microvascular Invasion and Earlier Recurrence with Higher Serum Autotaxin Levels.

Authors:  Kenichiro Enooku; Baasanjav Uranbileg; Hitoshi Ikeda; Makoto Kurano; Masaya Sato; Hiroki Kudo; Harufumi Maki; Kazuhiko Koike; Kiyoshi Hasegawa; Norihiro Kokudo; Yutaka Yatomi
Journal:  PLoS One       Date:  2016-09-01       Impact factor: 3.240

10.  Loss of lysophosphatidic acid receptor 1 in hepatocytes reduces steatosis via down-regulation of CD36.

Authors:  Ingrid Lua; Steven Balog; Ami Yanagi; Chise Tateno; Kinji Asahina
Journal:  Prostaglandins Other Lipid Mediat       Date:  2021-06-17       Impact factor: 3.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.